Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 18;108(11):e1450-e1451.
doi: 10.1210/clinem/dgad216.

SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI and Stroke

David T Broome  1
Affiliations
Editorial

SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI and Stroke

David T Broome. J Clin Endocrinol Metab. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Cefalu WT, Kaul S, Gerstein HC, et al. . Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2018; 41(1):14‐31. - PMC - PubMed
    1. Davies MJ, Aroda VR, Collins BS, et al. . Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the 327 American Diabetes Association (ADA) and the European Association for the Study of 328 Diabetes (EASD). Diabetes Care. 2022; 45(11):2753‐2786. - PMC - PubMed
    1. El Sayed NA, Aleppo G, Aroda VR, et al. . Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023; 46(Suppl_1):S140‐S157. - PMC - PubMed
    1. Mukhopadhyay P, Sanyal D, Chatterjee P, Pandit K, Ghosh S. SGLT2 inhibitors: effect on myocardial infarction and stroke in type 2 diabetes. J Clin Endocrinol Metab. 2023;108(8):2134-2140. - PubMed
    1. Zinman B, Wanner C, Lachin JM, et al. . EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117‐2128. - PubMed

Substances